nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CCR5—renal system—urinary bladder cancer	0.0384	0.279	CbGeAlD
Maraviroc—CCR5—Early Phase of HIV Life Cycle—LIG1—urinary bladder cancer	0.037	0.285	CbGpPWpGaD
Maraviroc—CYP3A4—Thiotepa—urinary bladder cancer	0.0342	0.687	CbGbCtD
Maraviroc—CCR5—female reproductive system—urinary bladder cancer	0.0307	0.223	CbGeAlD
Maraviroc—CCR5—vagina—urinary bladder cancer	0.0278	0.202	CbGeAlD
Maraviroc—CCR5—lymph node—urinary bladder cancer	0.018	0.131	CbGeAlD
Maraviroc—CYP3A4—urine—urinary bladder cancer	0.0158	0.115	CbGeAlD
Maraviroc—CYP3A4—Etoposide—urinary bladder cancer	0.00927	0.186	CbGbCtD
Maraviroc—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00687	0.053	CbGpPWpGaD
Maraviroc—CYP3A4—Doxorubicin—urinary bladder cancer	0.00632	0.127	CbGbCtD
Maraviroc—CCR5—HIV Life Cycle—LIG1—urinary bladder cancer	0.006	0.0463	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—LIG1—urinary bladder cancer	0.00415	0.032	CbGpPWpGaD
Maraviroc—CYP3A4—renal system—urinary bladder cancer	0.00387	0.0281	CbGeAlD
Maraviroc—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00359	0.0277	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—FAS—urinary bladder cancer	0.00353	0.0272	CbGpPWpGaD
Maraviroc—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00318	0.0245	CbGpPWpGaD
Maraviroc—CCR5—Chemokine receptors bind chemokines—CXCL8—urinary bladder cancer	0.00315	0.0243	CbGpPWpGaD
Maraviroc—CYP3A4—female reproductive system—urinary bladder cancer	0.0031	0.0225	CbGeAlD
Maraviroc—CCR5—HIV Infection—RBX1—urinary bladder cancer	0.003	0.0231	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—urinary bladder cancer	0.00284	0.0219	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—ERCC2—urinary bladder cancer	0.00266	0.0205	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00258	0.0199	CbGpPWpGaD
Maraviroc—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00226	0.0175	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00194	0.015	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—ERCC2—urinary bladder cancer	0.00184	0.0142	CbGpPWpGaD
Maraviroc—CCR5—Disease—GSTO2—urinary bladder cancer	0.00177	0.0136	CbGpPWpGaD
Maraviroc—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00139	0.0107	CbGpPWpGaD
Maraviroc—CCR5—Disease—SLC19A1—urinary bladder cancer	0.00138	0.0106	CbGpPWpGaD
Maraviroc—CCR5—Disease—PRSS3—urinary bladder cancer	0.00134	0.0103	CbGpPWpGaD
Maraviroc—CCR5—Disease—HDAC4—urinary bladder cancer	0.00128	0.00986	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—HRAS—urinary bladder cancer	0.00126	0.00974	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00123	0.00952	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00122	0.0094	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.00118	0.00913	CbGpPWpGaD
Maraviroc—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00106	0.0082	CbGpPWpGaD
Maraviroc—CCR5—Disease—LIG1—urinary bladder cancer	0.00102	0.00784	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.001	0.00772	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000999	0.0077	CbGpPWpGaD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000997	0.00769	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HDAC4—urinary bladder cancer	0.000896	0.00691	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000794	0.00612	CbGpPWpGaD
Maraviroc—CCR5—Disease—ENO2—urinary bladder cancer	0.000775	0.00598	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GLI1—urinary bladder cancer	0.00075	0.00579	CbGpPWpGaD
Maraviroc—CCR5—Disease—RBX1—urinary bladder cancer	0.000735	0.00567	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000681	0.00525	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000672	0.00518	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAG1—urinary bladder cancer	0.000657	0.00507	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000646	0.00498	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000646	0.00498	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000637	0.00491	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000605	0.00466	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000591	0.00455	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000582	0.00449	CbGpPWpGaD
Maraviroc—Bronchitis—Epirubicin—urinary bladder cancer	0.000551	0.000807	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—urinary bladder cancer	0.000549	0.000804	CcSEcCtD
Maraviroc—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000548	0.000803	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000548	0.000802	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—urinary bladder cancer	0.000546	0.000799	CcSEcCtD
Maraviroc—Infestation—Methotrexate—urinary bladder cancer	0.000546	0.000799	CcSEcCtD
Maraviroc—Depression—Methotrexate—urinary bladder cancer	0.000544	0.000797	CcSEcCtD
Maraviroc—Pancytopenia—Epirubicin—urinary bladder cancer	0.000544	0.000797	CcSEcCtD
Maraviroc—Pain—Cisplatin—urinary bladder cancer	0.000542	0.000794	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000541	0.000792	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000541	0.000792	CcSEcCtD
Maraviroc—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000538	0.000788	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—urinary bladder cancer	0.000536	0.000786	CcSEcCtD
Maraviroc—Neutropenia—Epirubicin—urinary bladder cancer	0.000536	0.000784	CcSEcCtD
Maraviroc—Dizziness—Thiotepa—urinary bladder cancer	0.000535	0.000783	CcSEcCtD
Maraviroc—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000534	0.000781	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000532	0.00078	CcSEcCtD
Maraviroc—Stomatitis—Methotrexate—urinary bladder cancer	0.000532	0.000779	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000532	0.0041	CbGpPWpGaD
Maraviroc—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00053	0.000777	CcSEcCtD
Maraviroc—Influenza—Doxorubicin—urinary bladder cancer	0.00053	0.000776	CcSEcCtD
Maraviroc—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000529	0.000775	CcSEcCtD
Maraviroc—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000525	0.000768	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000524	0.00404	CbGpPWpGaD
Maraviroc—Paraesthesia—Etoposide—urinary bladder cancer	0.000522	0.000764	CcSEcCtD
Maraviroc—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00052	0.000761	CcSEcCtD
Maraviroc—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000516	0.000756	CcSEcCtD
Maraviroc—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000516	0.000756	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RBX1—urinary bladder cancer	0.000514	0.00397	CbGpPWpGaD
Maraviroc—Vomiting—Thiotepa—urinary bladder cancer	0.000514	0.000753	CcSEcCtD
Maraviroc—Pneumonia—Epirubicin—urinary bladder cancer	0.000514	0.000752	CcSEcCtD
Maraviroc—Infestation—Epirubicin—urinary bladder cancer	0.000511	0.000748	CcSEcCtD
Maraviroc—Infestation NOS—Epirubicin—urinary bladder cancer	0.000511	0.000748	CcSEcCtD
Maraviroc—Rash—Thiotepa—urinary bladder cancer	0.00051	0.000747	CcSEcCtD
Maraviroc—Bronchitis—Doxorubicin—urinary bladder cancer	0.00051	0.000746	CcSEcCtD
Maraviroc—Dermatitis—Thiotepa—urinary bladder cancer	0.00051	0.000746	CcSEcCtD
Maraviroc—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000509	0.000746	CcSEcCtD
Maraviroc—Headache—Thiotepa—urinary bladder cancer	0.000507	0.000742	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000506	0.000741	CcSEcCtD
Maraviroc—Decreased appetite—Etoposide—urinary bladder cancer	0.000505	0.00074	CcSEcCtD
Maraviroc—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000503	0.000737	CcSEcCtD
Maraviroc—Renal failure—Epirubicin—urinary bladder cancer	0.000502	0.000735	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000502	0.000735	CcSEcCtD
Maraviroc—Body temperature increased—Cisplatin—urinary bladder cancer	0.000501	0.000734	CcSEcCtD
Maraviroc—Fatigue—Etoposide—urinary bladder cancer	0.000501	0.000734	CcSEcCtD
Maraviroc—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000501	0.000733	CcSEcCtD
Maraviroc—Stomatitis—Epirubicin—urinary bladder cancer	0.000498	0.000729	CcSEcCtD
Maraviroc—Jaundice—Epirubicin—urinary bladder cancer	0.000498	0.000729	CcSEcCtD
Maraviroc—Constipation—Etoposide—urinary bladder cancer	0.000497	0.000728	CcSEcCtD
Maraviroc—Pain—Etoposide—urinary bladder cancer	0.000497	0.000728	CcSEcCtD
Maraviroc—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000496	0.000727	CcSEcCtD
Maraviroc—Neutropenia—Doxorubicin—urinary bladder cancer	0.000496	0.000726	CcSEcCtD
Maraviroc—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000493	0.000722	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000493	0.000721	CcSEcCtD
Maraviroc—Asthenia—Gemcitabine—urinary bladder cancer	0.000488	0.000715	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—urinary bladder cancer	0.000486	0.000712	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000484	0.000708	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TSC1—urinary bladder cancer	0.000484	0.00373	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000483	0.000707	CcSEcCtD
Maraviroc—Pruritus—Gemcitabine—urinary bladder cancer	0.000481	0.000705	CcSEcCtD
Maraviroc—Nausea—Thiotepa—urinary bladder cancer	0.00048	0.000704	CcSEcCtD
Maraviroc—Urethral disorder—Methotrexate—urinary bladder cancer	0.00048	0.000703	CcSEcCtD
Maraviroc—Sinusitis—Epirubicin—urinary bladder cancer	0.000479	0.000702	CcSEcCtD
Maraviroc—CCR5—Disease—NCOR1—urinary bladder cancer	0.000479	0.00369	CbGpPWpGaD
Maraviroc—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000477	0.000698	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—urinary bladder cancer	0.000475	0.000696	CcSEcCtD
Maraviroc—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000475	0.000696	CcSEcCtD
Maraviroc—Pruritus—Fluorouracil—urinary bladder cancer	0.000473	0.000693	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000473	0.000692	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—urinary bladder cancer	0.000473	0.000692	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000468	0.000686	CcSEcCtD
Maraviroc—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000467	0.000684	CcSEcCtD
Maraviroc—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000466	0.000682	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—urinary bladder cancer	0.000465	0.00068	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000463	0.000678	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000463	0.000678	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—urinary bladder cancer	0.000461	0.000675	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—urinary bladder cancer	0.000461	0.000675	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—JAG1—urinary bladder cancer	0.00046	0.00355	CbGpPWpGaD
Maraviroc—Rhinitis—Epirubicin—urinary bladder cancer	0.00046	0.000673	CcSEcCtD
Maraviroc—Body temperature increased—Etoposide—urinary bladder cancer	0.000459	0.000673	CcSEcCtD
Maraviroc—Abdominal pain—Etoposide—urinary bladder cancer	0.000459	0.000673	CcSEcCtD
Maraviroc—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000459	0.000673	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000458	0.00353	CbGpPWpGaD
Maraviroc—Eye disorder—Methotrexate—urinary bladder cancer	0.000458	0.00067	CcSEcCtD
Maraviroc—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000458	0.00067	CcSEcCtD
Maraviroc—Asthenia—Cisplatin—urinary bladder cancer	0.000455	0.000666	CcSEcCtD
Maraviroc—Pharyngitis—Epirubicin—urinary bladder cancer	0.000455	0.000666	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000455	0.000666	CcSEcCtD
Maraviroc—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000453	0.000663	CcSEcCtD
Maraviroc—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000451	0.00066	CcSEcCtD
Maraviroc—CCR5—Disease—ERCC2—urinary bladder cancer	0.00045	0.00347	CbGpPWpGaD
Maraviroc—Urethral disorder—Epirubicin—urinary bladder cancer	0.000449	0.000658	CcSEcCtD
Maraviroc—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000447	0.000654	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—urinary bladder cancer	0.000444	0.000651	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—urinary bladder cancer	0.000443	0.000649	CcSEcCtD
Maraviroc—Dizziness—Fluorouracil—urinary bladder cancer	0.000442	0.000648	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000442	0.000647	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000441	0.000646	CcSEcCtD
Maraviroc—Diarrhoea—Cisplatin—urinary bladder cancer	0.000434	0.000636	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000433	0.000635	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—urinary bladder cancer	0.000433	0.000634	CcSEcCtD
Maraviroc—Vomiting—Gemcitabine—urinary bladder cancer	0.000433	0.000634	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—urinary bladder cancer	0.000429	0.000629	CcSEcCtD
Maraviroc—Rash—Gemcitabine—urinary bladder cancer	0.000429	0.000628	CcSEcCtD
Maraviroc—Dermatitis—Gemcitabine—urinary bladder cancer	0.000429	0.000628	CcSEcCtD
Maraviroc—Eye disorder—Epirubicin—urinary bladder cancer	0.000428	0.000627	CcSEcCtD
Maraviroc—Hypersensitivity—Etoposide—urinary bladder cancer	0.000428	0.000627	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—urinary bladder cancer	0.000426	0.000625	CcSEcCtD
Maraviroc—Erythema—Methotrexate—urinary bladder cancer	0.000426	0.000625	CcSEcCtD
Maraviroc—Headache—Gemcitabine—urinary bladder cancer	0.000426	0.000624	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000425	0.000623	CcSEcCtD
Maraviroc—Vomiting—Fluorouracil—urinary bladder cancer	0.000425	0.000623	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—urinary bladder cancer	0.000425	0.000623	CcSEcCtD
Maraviroc—CCR5—Disease—MTHFR—urinary bladder cancer	0.000423	0.00326	CbGpPWpGaD
Maraviroc—CCR5—Disease—TERT—urinary bladder cancer	0.000422	0.00325	CbGpPWpGaD
Maraviroc—Rash—Fluorouracil—urinary bladder cancer	0.000422	0.000618	CcSEcCtD
Maraviroc—Dermatitis—Fluorouracil—urinary bladder cancer	0.000421	0.000617	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000421	0.000617	CcSEcCtD
Maraviroc—Headache—Fluorouracil—urinary bladder cancer	0.000419	0.000614	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000419	0.000613	CcSEcCtD
Maraviroc—Asthenia—Etoposide—urinary bladder cancer	0.000417	0.000611	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000417	0.00061	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—urinary bladder cancer	0.000416	0.000609	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000416	0.000609	CcSEcCtD
Maraviroc—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000413	0.000605	CcSEcCtD
Maraviroc—Pruritus—Etoposide—urinary bladder cancer	0.000411	0.000602	CcSEcCtD
Maraviroc—Alopecia—Epirubicin—urinary bladder cancer	0.000405	0.000593	CcSEcCtD
Maraviroc—Nausea—Gemcitabine—urinary bladder cancer	0.000404	0.000592	CcSEcCtD
Maraviroc—Vomiting—Cisplatin—urinary bladder cancer	0.000403	0.000591	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—urinary bladder cancer	0.000402	0.000588	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000401	0.000587	CcSEcCtD
Maraviroc—Rash—Cisplatin—urinary bladder cancer	0.0004	0.000586	CcSEcCtD
Maraviroc—Dermatitis—Cisplatin—urinary bladder cancer	0.0004	0.000585	CcSEcCtD
Maraviroc—Erythema—Epirubicin—urinary bladder cancer	0.000399	0.000584	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—urinary bladder cancer	0.000399	0.000584	CcSEcCtD
Maraviroc—Diarrhoea—Etoposide—urinary bladder cancer	0.000398	0.000582	CcSEcCtD
Maraviroc—Nausea—Fluorouracil—urinary bladder cancer	0.000397	0.000582	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—urinary bladder cancer	0.000396	0.000581	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—urinary bladder cancer	0.000394	0.000577	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000394	0.000577	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—urinary bladder cancer	0.000393	0.000576	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000389	0.003	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGFR3—urinary bladder cancer	0.000387	0.00299	CbGpPWpGaD
Maraviroc—Angiopathy—Doxorubicin—urinary bladder cancer	0.000385	0.000564	CcSEcCtD
Maraviroc—Dizziness—Etoposide—urinary bladder cancer	0.000384	0.000563	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000382	0.00056	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—urinary bladder cancer	0.000382	0.000559	CcSEcCtD
Maraviroc—Nausea—Cisplatin—urinary bladder cancer	0.000377	0.000552	CcSEcCtD
Maraviroc—Alopecia—Doxorubicin—urinary bladder cancer	0.000375	0.000549	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—S100B—urinary bladder cancer	0.000373	0.00288	CbGpPWpGaD
Maraviroc—Cough—Methotrexate—urinary bladder cancer	0.000372	0.000545	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—urinary bladder cancer	0.000372	0.000544	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—urinary bladder cancer	0.000369	0.000541	CcSEcCtD
Maraviroc—Vomiting—Etoposide—urinary bladder cancer	0.000369	0.000541	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—urinary bladder cancer	0.000369	0.000541	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—urinary bladder cancer	0.000369	0.000541	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—urinary bladder cancer	0.000369	0.00054	CcSEcCtD
Maraviroc—Rash—Etoposide—urinary bladder cancer	0.000366	0.000537	CcSEcCtD
Maraviroc—Dermatitis—Etoposide—urinary bladder cancer	0.000366	0.000536	CcSEcCtD
Maraviroc—Headache—Etoposide—urinary bladder cancer	0.000364	0.000533	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—urinary bladder cancer	0.000364	0.000533	CcSEcCtD
Maraviroc—Myalgia—Methotrexate—urinary bladder cancer	0.000363	0.000532	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000361	0.000528	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—urinary bladder cancer	0.000359	0.000525	CcSEcCtD
Maraviroc—Syncope—Epirubicin—urinary bladder cancer	0.000358	0.000524	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—urinary bladder cancer	0.000357	0.000523	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000354	0.00273	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RHOA—urinary bladder cancer	0.000353	0.00273	CbGpPWpGaD
Maraviroc—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000351	0.000514	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000349	0.00269	CbGpPWpGaD
Maraviroc—Cough—Epirubicin—urinary bladder cancer	0.000348	0.00051	CcSEcCtD
Maraviroc—Convulsion—Epirubicin—urinary bladder cancer	0.000346	0.000506	CcSEcCtD
Maraviroc—Infection—Methotrexate—urinary bladder cancer	0.000346	0.000506	CcSEcCtD
Maraviroc—Nausea—Etoposide—urinary bladder cancer	0.000345	0.000505	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000342	0.00264	CbGpPWpGaD
Maraviroc—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000341	0.0005	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—urinary bladder cancer	0.000341	0.0005	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—urinary bladder cancer	0.00034	0.000498	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—urinary bladder cancer	0.000339	0.000496	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—urinary bladder cancer	0.000338	0.000495	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000337	0.000494	CcSEcCtD
Maraviroc—Discomfort—Epirubicin—urinary bladder cancer	0.000336	0.000492	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NCOR1—urinary bladder cancer	0.000335	0.00259	CbGpPWpGaD
Maraviroc—Anorexia—Methotrexate—urinary bladder cancer	0.000332	0.000486	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—urinary bladder cancer	0.000331	0.000485	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—urinary bladder cancer	0.000331	0.000484	CcSEcCtD
Maraviroc—CCR5—Disease—CREBBP—urinary bladder cancer	0.00033	0.00254	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—urinary bladder cancer	0.000327	0.00252	CbGpPWpGaD
Maraviroc—Oedema—Epirubicin—urinary bladder cancer	0.000326	0.000477	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000325	0.000475	CcSEcCtD
Maraviroc—Infection—Epirubicin—urinary bladder cancer	0.000324	0.000474	CcSEcCtD
Maraviroc—Cough—Doxorubicin—urinary bladder cancer	0.000322	0.000472	CcSEcCtD
Maraviroc—Shock—Epirubicin—urinary bladder cancer	0.00032	0.000469	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—urinary bladder cancer	0.00032	0.000469	CcSEcCtD
Maraviroc—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000319	0.000468	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000317	0.000464	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—urinary bladder cancer	0.000316	0.000463	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—urinary bladder cancer	0.000315	0.000461	CcSEcCtD
Maraviroc—Myalgia—Doxorubicin—urinary bladder cancer	0.000314	0.00046	CcSEcCtD
Maraviroc—Anxiety—Doxorubicin—urinary bladder cancer	0.000313	0.000459	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—urinary bladder cancer	0.000313	0.000458	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000312	0.000457	CcSEcCtD
Maraviroc—Discomfort—Doxorubicin—urinary bladder cancer	0.000311	0.000455	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—urinary bladder cancer	0.00031	0.000455	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—urinary bladder cancer	0.00031	0.00239	CbGpPWpGaD
Maraviroc—Decreased appetite—Methotrexate—urinary bladder cancer	0.000303	0.000443	CcSEcCtD
Maraviroc—Oedema—Doxorubicin—urinary bladder cancer	0.000301	0.000441	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.0003	0.00044	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—urinary bladder cancer	0.0003	0.000439	CcSEcCtD
Maraviroc—Infection—Doxorubicin—urinary bladder cancer	0.000299	0.000438	CcSEcCtD
Maraviroc—CCR5—Disease—RHOA—urinary bladder cancer	0.000298	0.0023	CbGpPWpGaD
Maraviroc—Pain—Methotrexate—urinary bladder cancer	0.000298	0.000436	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000297	0.000435	CcSEcCtD
Maraviroc—Shock—Doxorubicin—urinary bladder cancer	0.000297	0.000434	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—IL2—urinary bladder cancer	0.000297	0.00229	CbGpPWpGaD
Maraviroc—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000296	0.000433	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TERT—urinary bladder cancer	0.000295	0.00228	CbGpPWpGaD
Maraviroc—Insomnia—Epirubicin—urinary bladder cancer	0.000295	0.000431	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—urinary bladder cancer	0.000293	0.000429	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—urinary bladder cancer	0.000292	0.000428	CcSEcCtD
Maraviroc—Anorexia—Doxorubicin—urinary bladder cancer	0.000287	0.000421	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000285	0.000417	CcSEcCtD
Maraviroc—Decreased appetite—Epirubicin—urinary bladder cancer	0.000283	0.000415	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000283	0.00218	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000281	0.000412	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—urinary bladder cancer	0.000281	0.000411	CcSEcCtD
Maraviroc—Pain—Epirubicin—urinary bladder cancer	0.000279	0.000408	CcSEcCtD
Maraviroc—Constipation—Epirubicin—urinary bladder cancer	0.000279	0.000408	CcSEcCtD
Maraviroc—CCR5—Disease—ERBB2—urinary bladder cancer	0.000276	0.00213	CbGpPWpGaD
Maraviroc—Abdominal pain—Methotrexate—urinary bladder cancer	0.000275	0.000403	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—urinary bladder cancer	0.000275	0.000403	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000275	0.000402	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000274	0.00212	CbGpPWpGaD
Maraviroc—Insomnia—Doxorubicin—urinary bladder cancer	0.000273	0.000399	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FGFR3—urinary bladder cancer	0.000271	0.00209	CbGpPWpGaD
Maraviroc—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000271	0.000396	CcSEcCtD
Maraviroc—CCR5—Disease—PTGS2—urinary bladder cancer	0.00027	0.00208	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000266	0.00039	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ESR1—urinary bladder cancer	0.000263	0.00203	CbGpPWpGaD
Maraviroc—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000262	0.000384	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00026	0.000381	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—urinary bladder cancer	0.00026	0.000381	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—urinary bladder cancer	0.000258	0.000377	CcSEcCtD
Maraviroc—Pain—Doxorubicin—urinary bladder cancer	0.000258	0.000377	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—urinary bladder cancer	0.000257	0.000377	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—urinary bladder cancer	0.000257	0.000377	CcSEcCtD
Maraviroc—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000256	0.000376	CcSEcCtD
Maraviroc—Asthenia—Methotrexate—urinary bladder cancer	0.00025	0.000366	CcSEcCtD
Maraviroc—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000246	0.000361	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—urinary bladder cancer	0.000246	0.000361	CcSEcCtD
Maraviroc—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00024	0.000351	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000238	0.000349	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000238	0.000349	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—urinary bladder cancer	0.000238	0.000349	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN1A—urinary bladder cancer	0.000236	0.00182	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—urinary bladder cancer	0.000235	0.00182	CbGpPWpGaD
Maraviroc—Asthenia—Epirubicin—urinary bladder cancer	0.000234	0.000342	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CREBBP—urinary bladder cancer	0.000231	0.00178	CbGpPWpGaD
Maraviroc—Pruritus—Epirubicin—urinary bladder cancer	0.00023	0.000337	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—urinary bladder cancer	0.00023	0.000337	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF1—urinary bladder cancer	0.000228	0.00176	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—urinary bladder cancer	0.000227	0.00175	CbGpPWpGaD
Maraviroc—CCR5—Disease—EP300—urinary bladder cancer	0.000224	0.00173	CbGpPWpGaD
Maraviroc—Diarrhoea—Epirubicin—urinary bladder cancer	0.000223	0.000326	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000222	0.000325	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—urinary bladder cancer	0.000221	0.000324	CcSEcCtD
Maraviroc—Rash—Methotrexate—urinary bladder cancer	0.000219	0.000321	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—urinary bladder cancer	0.000219	0.000321	CcSEcCtD
Maraviroc—CCR5—Disease—SRC—urinary bladder cancer	0.000218	0.00168	CbGpPWpGaD
Maraviroc—Headache—Methotrexate—urinary bladder cancer	0.000218	0.000319	CcSEcCtD
Maraviroc—Asthenia—Doxorubicin—urinary bladder cancer	0.000216	0.000317	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—urinary bladder cancer	0.000215	0.000315	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—KRAS—urinary bladder cancer	0.000214	0.00165	CbGpPWpGaD
Maraviroc—Pruritus—Doxorubicin—urinary bladder cancer	0.000213	0.000312	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RHOA—urinary bladder cancer	0.000209	0.00161	CbGpPWpGaD
Maraviroc—Vomiting—Epirubicin—urinary bladder cancer	0.000207	0.000303	CcSEcCtD
Maraviroc—Nausea—Methotrexate—urinary bladder cancer	0.000207	0.000303	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000206	0.000302	CcSEcCtD
Maraviroc—Rash—Epirubicin—urinary bladder cancer	0.000205	0.000301	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—urinary bladder cancer	0.000205	0.0003	CcSEcCtD
Maraviroc—Headache—Epirubicin—urinary bladder cancer	0.000204	0.000299	CcSEcCtD
Maraviroc—Dizziness—Doxorubicin—urinary bladder cancer	0.000199	0.000292	CcSEcCtD
Maraviroc—CCR5—Disease—MYC—urinary bladder cancer	0.000196	0.00151	CbGpPWpGaD
Maraviroc—Nausea—Epirubicin—urinary bladder cancer	0.000193	0.000283	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ERBB2—urinary bladder cancer	0.000193	0.00149	CbGpPWpGaD
Maraviroc—Vomiting—Doxorubicin—urinary bladder cancer	0.000192	0.000281	CcSEcCtD
Maraviroc—CCR5—Disease—EGFR—urinary bladder cancer	0.000191	0.00148	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.00019	0.00147	CbGpPWpGaD
Maraviroc—Rash—Doxorubicin—urinary bladder cancer	0.00019	0.000278	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—urinary bladder cancer	0.00019	0.000278	CcSEcCtD
Maraviroc—Headache—Doxorubicin—urinary bladder cancer	0.000189	0.000276	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000188	0.00145	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL8—urinary bladder cancer	0.000183	0.00141	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—urinary bladder cancer	0.000182	0.0014	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—urinary bladder cancer	0.000181	0.00139	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—urinary bladder cancer	0.000179	0.000262	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL2—urinary bladder cancer	0.000175	0.00135	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000175	0.00135	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000172	0.00133	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—urinary bladder cancer	0.000171	0.00132	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—urinary bladder cancer	0.000166	0.00128	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000165	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—urinary bladder cancer	0.000165	0.00127	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EP300—urinary bladder cancer	0.000157	0.00121	CbGpPWpGaD
Maraviroc—CCR5—Disease—HRAS—urinary bladder cancer	0.000154	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SRC—urinary bladder cancer	0.000153	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MYC—urinary bladder cancer	0.000137	0.00106	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—urinary bladder cancer	0.000134	0.00103	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KRAS—urinary bladder cancer	0.000127	0.000976	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.000898	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—urinary bladder cancer	0.000112	0.000868	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.000852	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.00011	0.000852	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—urinary bladder cancer	0.000108	0.00083	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	0.000101	0.000779	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.09e-05	0.000701	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	8.59e-05	0.000662	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.37e-05	0.000645	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.69e-05	0.000516	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.05e-05	0.000467	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.22e-05	0.000403	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.84e-05	0.000373	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.84e-05	0.000373	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.69e-05	0.000362	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.9e-05	0.000301	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.25e-05	0.000251	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.02e-05	0.000233	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.99e-05	0.00023	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.99e-05	0.00023	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.86e-05	0.000221	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.81e-05	0.000217	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.64e-05	0.000204	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.14e-05	0.000165	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.06e-05	0.000159	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.68e-05	0.00013	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.47e-05	0.000113	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.4e-05	0.000108	CbGpPWpGaD
